Infliximab for maintenance therapy for treatment of Crohn's disease: a review of the clinical effectiveness and guidelines
Canadian Agency for Drugs and Technologies in Health
Record ID 32011001174
English
Authors' recommendations:
Observational studies have reported that response to infliximab is regained after the dose is increased, or dosing frequency is increased. A Canadian clinical practice guideline supports the practice of dose escalation in the event of loss of response. The CADTH HTA and current Canadian guidelines appear to be using the same studies to draw conclusions regarding the effectiveness of infliximab dose escalation in Crohn’s disease. The economic impact of infliximab dose escalation was not considered in the Canadian guidelines and this may be an issue for policy consideration since it could double drug costs. The limited information from controlled studies about infliximab dose escalation may be a consideration for decision-making.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.cadth.ca/media/pdf/l0180_infliximab_crohn's_disease_htis-2.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antibodies, Monoclonal
- Remission Induction
- Treatment Outcome
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.